Literature DB >> 26862501

Sublingual immunotherapy for pediatric allergic rhinitis: The clinical evidence.

Dimitri Poddighe1, Amelia Licari1, Silvia Caimmi1, Gian Luigi Marseglia1.   

Abstract

Allergic rhinitis is estimated to affect 10%-20% of pediatric population and it is caused by the IgE-sensitization to environmental allergens, most importantly grass pollens and house dust mites. Allergic rhinitis can influence patient's daily activity severely and may precede the development of asthma, especially if it is not diagnosed and treated correctly. In addition to subcutaneous immunotherapy, sublingual immunotherapy (SLIT) represents the only treatment being potentially able to cure allergic respiratory diseases, by modulating the immune system activity. This review clearly summarizes and analyzes the available randomized, double-blinded, placebo-controlled trials, which aimed at evaluating the effectiveness and the safety of grass pollen and house dust mite SLIT for the specific treatment of pediatric allergic rhinitis. Our analysis demonstrates the good evidence supporting the efficacy of SLIT for allergic rhinitis to grass pollens in children, whereas trials regarding pediatric allergic rhinitis to house dust mites present lower quality, although several studies supported its usefulness.

Entities:  

Keywords:  Allergic rhinitis; Grass pollen allergy; House dust mite allergy; Sublingual immunotherapy

Year:  2016        PMID: 26862501      PMCID: PMC4737692          DOI: 10.5409/wjcp.v5.i1.47

Source DB:  PubMed          Journal:  World J Clin Pediatr        ISSN: 2219-2808


  45 in total

Review 1.  Preventing progression of allergic rhinitis to asthma.

Authors:  Jaymin B Morjaria; Massimo Caruso; Emma Rosalia; Cristina Russo; Riccardo Polosa
Journal:  Curr Allergy Asthma Rep       Date:  2014-02       Impact factor: 4.806

2.  Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials.

Authors:  Martin Penagos; Enrico Compalati; Francesco Tarantini; Rodrigo Baena-Cagnani; Jose Huerta; Giovanni Passalacqua; Giorgio Walter Canonica
Journal:  Ann Allergy Asthma Immunol       Date:  2006-08       Impact factor: 6.347

3.  Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis.

Authors:  Ji-Eun Lee; Yoon-Seok Choi; Min-Su Kim; Doo Hee Han; Chae-Seo Rhee; Chul Hee Lee; Dong-Young Kim
Journal:  Ann Allergy Asthma Immunol       Date:  2011-04-22       Impact factor: 6.347

Review 4.  Sublingual immunotherapy in children: the recent experiences.

Authors:  Nicole Pleskovic; Ashton Bartholow; David P Skoner
Journal:  Curr Opin Allergy Clin Immunol       Date:  2014-12

5.  Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children.

Authors:  Syuji Yonekura; Yoshitaka Okamoto; Daiju Sakurai; Shigetoshi Horiguchi; Toyoyuki Hanazawa; Atsuko Nakano; Fumiyo Kudou; Yuji Nakamaru; Kohei Honda; Akira Hoshioka; Naoki Shimojo; Yoichi Kohno
Journal:  Allergol Int       Date:  2010-09-25       Impact factor: 5.836

6.  Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents.

Authors:  Michael Blaiss; Jennifer Maloney; Hendrik Nolte; Sandra Gawchik; Ruji Yao; David P Skoner
Journal:  J Allergy Clin Immunol       Date:  2011-01       Impact factor: 10.793

7.  Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.

Authors:  A Bufe; E Ziegler-Kirbach; E Stoeckmann; P Heidemann; K Gehlhar; T Holland-Letz; W Braun
Journal:  Allergy       Date:  2004-05       Impact factor: 13.146

8.  Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.

Authors:  Albrecht Bufe; Peter Eberle; Eivy Franke-Beckmann; Jürgen Funck; Martin Kimmig; Ludger Klimek; Roland Knecht; Volker Stephan; Bente Tholstrup; Christian Weisshaar; Friedrich Kaiser
Journal:  J Allergy Clin Immunol       Date:  2009-01       Impact factor: 10.793

9.  Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period.

Authors:  Y Nuhoglu; S S Ozumut; C Ozdemir; M Ozdemir; C Nuhoglu; M Erguven
Journal:  J Investig Allergol Clin Immunol       Date:  2007       Impact factor: 4.333

10.  The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children.

Authors:  Jacques Hébert; Michael Blaiss; Susan Waserman; Harold Kim; Peter Creticos; Jennifer Maloney; Amarjot Kaur; Ziliang Li; Harold Nelson; Hendrik Nolte
Journal:  Allergy Asthma Clin Immunol       Date:  2014-10-30       Impact factor: 3.406

View more
  5 in total

Review 1.  Non-allergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management.

Authors:  Dimitri Poddighe; Matteo Gelardi; Amelia Licari; Michele Miraglia Del Giudice; Gian Luigi Marseglia
Journal:  World J Methodol       Date:  2016-12-26

Review 2.  Novel therapeutic targets for allergic airway disease in children.

Authors:  Alessandro Giallongo; Giuseppe Fabio Parisi; Amelia Licari; Giulio Pulvirenti; Caterina Cuppari; Carmelo Salpietro; Gian Luigi Marseglia; Salvatore Leonardi
Journal:  Drugs Context       Date:  2019-07-09

3.  Sublingual immunotherapy for pediatric patients with mite allergies.

Authors:  Teruyuki Kajiume
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

Review 4.  Ma-Huang-Fu-Zi-Xi-Xin Decoction for Allergic Rhinitis: A Systematic Review.

Authors:  Juan Zhong; Dan Lai; Yun Zheng; Gang Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-05       Impact factor: 2.629

5.  Gui-zhi decoction for allergic rhinitis: A protocol for systematic review and meta analysis.

Authors:  Bin Zou; Wentao Zhang; Yuechuan Cai; Fubing Zhang; Chengrui Wang
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.